Bone News and Research

RSS

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration.

5 Oct 2014

Diet may influence susceptibility to autoinflammatory bone disease in at-risk individuals

Diet-induced changes in the gut's bacterial ecosystem can alter susceptibility to an autoinflammatory bone disease by modifying the immune response, St. Jude Children's Research Hospital scientists reported. The findings appeared September 28 as an advanced online publication of the scientific journal Nature.

3 Oct 2014

Lucideon announces successful development of bioceramics for bone repair

As a partner in the EU-funded Bio-Bone project (Bioceramics for Bone Repair) Lucideon is pleased to announce that the pan-European consortium has successfully developed phosphate-glasses (p-glasses) with biomaterial properties for bone repair.

From Lucideon 3 Oct 2014

Placenta-derived cells are safe for MS patients

Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders.

1 Oct 2014

Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease is the most common condition within a family of rare diseases known as the lysosomal storage diseases. The disease causes lipids to accumulate in cells, which is why it is referred to as a storage disorder. The accumulation occurs mainly in the spleen, liver, and bones, but may also occur in the lungs, heart, and central nervous system.

30 Sep 2014

Gut microbe in patients may tip doctors about SCID

Many people recognize "the bubble boy" as an unusual character from a "Seinfeld" episode or a John Travolta movie.

30 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease.

26 Sep 2014

Anti-inflammatory treatment may prevent heterotopic ossification

An anti-inflammatory treatment, studied in the labs of regenerative medicine specialists and trauma surgeons, may prevent what's become one of the war-defining injuries for today's troops.

26 Sep 2014

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

Sumitomo Dainippon Pharma Co., Ltd. and SanBio Co., Ltd., acting through its U.S. subsidiary SanBio, Inc., announced on September 26 that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S. and Canada ("Agreement") for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio.

26 Sep 2014

New approach to create treatments for osteoporosis, autoimmune diseases

Scientists have developed an approach to creating treatments for osteoporosis and autoimmune diseases that may avoid the risk of infection and cancer posed by some current medications.

26 Sep 2014

Novel treatment makes life-saving difference to young patients with Ph-like ALL

St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype associated with a poor outcome.

24 Sep 2014

Rice University research yields new two-step strategy for weakening cancer

Research by Rice University scientists who are fighting a cyberwar against cancer finds that the immune system may be a clinician's most powerful ally.

24 Sep 2014

MU study reinforces importance of early hearing interventions

Infants' vocalizations throughout the first year follow a set of predictable steps from crying and cooing to forming syllables and first words. However, previous research had not addressed how the amount of vocalizations may differ between hearing and deaf infants.

24 Sep 2014

Scientists identify gene mutation that causes aplastic anemia

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells.

23 Sep 2014

Misonix provides ultrasonic BoneScalpel to support Uganda Spine Surgery Mission

Misonix, Inc., an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announces that it has once again supported the Uganda Spine Surgery Mission organized by leading spine surgeon Dr. Isador Lieberman, from the Texas Back Institute in Plano, TX, by providing an ultrasonic BoneScalpel for use in a number of advanced spinal surgeries.

23 Sep 2014

Research findings provide avenue for targeted therapy to treat AML

A novel study by the Cancer Science Institute of Singapore at the National University of Singapore found that an increase in a gene known as Leo1 affects other genes that are directly implicated in acute myelogenous leukaemia (AML), increasing the incidence of cancer.

23 Sep 2014

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.

22 Sep 2014

$DePuy Synthes releases new variable angle plating systems for calcaneal fractures, fusion procedures$

DePuy Synthes releases new variable angle plating systems for calcaneal fractures, fusion procedures

Today DePuy Synthes Companies of Johnson & Johnson launched two new variable angle plating systems featuring its proprietary variable angle locking technology. With this technology, surgeons can adapt screw trajectory to match patient anatomy and fracture pattern and angulate screws towards specific fragments of bone.

22 Sep 2014